Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1992 3
1993 1
1995 2
1997 1
1998 4
1999 2
2000 2
2001 2
2002 2
2003 2
2004 3
2005 3
2006 2
2007 1
2008 2
2009 3
2010 5
2011 5
2012 5
2013 2
2014 4
2015 11
2016 6
2017 7
2018 7
2019 10
2020 18
2021 21
2022 24
2023 19
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Rodriguez-Otero P, et al. Among authors: callander n. N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10. N Engl J Med. 2023. PMID: 36762851 Clinical Trial.
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.
Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK. Callander NS, et al. J Natl Compr Canc Netw. 2022 Jan;20(1):8-19. doi: 10.6004/jnccn.2022.0002. J Natl Compr Canc Netw. 2022. PMID: 34991075
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS. Costa LJ, et al. Among authors: callander ns. J Clin Oncol. 2022 Sep 1;40(25):2901-2912. doi: 10.1200/JCO.21.01935. Epub 2021 Dec 13. J Clin Oncol. 2022. PMID: 34898239 Clinical Trial.
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ. Gandhi UH, et al. Among authors: callander ns. Leukemia. 2019 Sep;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11. Leukemia. 2019. PMID: 30858549 Free PMC article.
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R, Snedeker J. Kumar SK, et al. Among authors: callander ns. J Natl Compr Canc Netw. 2023 Dec;21(12):1281-1301. doi: 10.6004/jnccn.2023.0061. J Natl Compr Canc Netw. 2023. PMID: 38081133
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Kang Y, Hultcrantz M, Larson S, Liedtke M, Martin T, Omel J, Shain K, Sborov D, Stockerl-Goldstein K, Weber D, Keller J, Kumar R. Kumar SK, et al. Among authors: callander ns. J Natl Compr Canc Netw. 2020 Dec 2;18(12):1685-1717. doi: 10.6004/jnccn.2020.0057. J Natl Compr Canc Netw. 2020. PMID: 33285522
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD. Lonial S, et al. Among authors: callander n. Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16. Lancet Oncol. 2020. PMID: 31859245 Clinical Trial.
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.
Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, Usmani S, Kumar S. Dhakal B, et al. Among authors: callander n. Transplant Cell Ther. 2022 Jun;28(6):284-293. doi: 10.1016/j.jtct.2022.03.019. Epub 2022 Mar 17. Transplant Cell Ther. 2022. PMID: 35306217 Free article.
160 results